Omnicell Inc. Stock
Omnicell Inc. Stock
We can see a decrease in the price for Omnicell Inc.. Compared to yesterday it has lost -€0.600 (-1.760%).
With 11 Buy predictions and not the single Sell prediction the community is currently very high on Omnicell Inc..
With a target price of 37 € there is a slightly positive potential of 10.78% for Omnicell Inc. compared to the current price of 33.4 €.
Pros and Cons of Omnicell Inc. in the next few years
Pros
?
M***** P*******
?
B****
?
G***** c******* t* c**********
Cons
?
S********** s********
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Omnicell Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Omnicell Inc. | -1.760% | 11.111% | -21.296% | -9.091% | -12.371% | -32.000% | -67.619% |
| Healthequity Inc. | -0.760% | 6.452% | -9.589% | -35.922% | -15.385% | 7.317% | 1.538% |
| Bruker Corp. | 0.000% | 5.660% | -26.764% | -33.141% | -20.373% | - | - |
| Myriad Genetics | -2.200% | -2.674% | -28.627% | -73.235% | -31.321% | -78.632% | -85.203% |
Comments
Omnicell (NASDAQ:OMCL) was upgraded by analysts at Bank of America Corporation from a "neutral" rating to a "buy" rating. They now have a $70.00 price target on the stock.
Show more
Ratings data for OMCL provided by MarketBeat
Omnicell (NASDAQ:OMCL) had its "buy" rating reaffirmed by analysts at Benchmark Co..
Show more
Ratings data for OMCL provided by MarketBeat
Omnicell (NASDAQ:OMCL) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
Show more
Ratings data for OMCL provided by MarketBeat
News
Omnicell Executive Trims Holdings in $244,000 Sale as Stock Trades Near 2025 Highs
Corey J Manley, EVP & Chief Legal/Admin Officer at Omnicell (NASDAQ:OMCL), executed an open-market sale of 6,106 shares for $243,629.40 on Dec. 3, 2025, as reported in the SEC Form 4 filing.
Why Omnicell Stock Crushed the Market Today
Healthcare tech company Omnicell (NASDAQ: OMCL) was quite the picture of health on Thursday, at least as far as its equity was concerned. An encouraging quarterly earnings report sent its shares